Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for Mounjaro ...

The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

Since 2007, the contract laboratory Alphalyse A/S has developed and refined a new method of impurity analysis in biological ...

GV Research Platform (GVRP), a leading provider of preclinical research solutions, has announced a strategic partnership with ...

Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations as part of ...

Pharmacies play a key role in improving drug development and patient care, offering insights, clinical trial support and ...

Zenas BioPharma, Inc.’s ZBIO share price has surged by 13.37%, which has investors questioning if this is right time to sell.

GTB-3650 is GT Biopharma's wholly owned second-generation TriKE. It utilizes camelid nanobody technology, with the potential ...